Nyheter/rapporter

Senaste pressmeddelanden och rapporter för bevakat bolag.

Datum Källa Rubrik Typ Alternativ
2019-06-26 Diamyd Medical Diamyd Medical AB: Quarterly Report III 18/19 Rapporter Ladda ner | Visa Stäng
2019-06-26 Diamyd Medical Diamyd Medical AB: Delårsrapport III 18/19 Rapporter Ladda ner | Visa Stäng
2019-06-18 Diamyd Medical Diamyd Medical AB: Diamyd Medicals intralymfatiska diabetesterapi väcker ökat intresse Pressreleaser Ladda ner | Visa Stäng
2019-06-18 Diamyd Medical Diamyd Medical AB: Diamyd Medical's intralymphatic diabetes therapy attracts increased interest Pressreleaser Ladda ner | Visa Stäng
2019-06-10 Diamyd Medical Diamyd Medical AB: Diamyd Medical fully subscribes to its pro rata share in NextCell Pharma's rights issue Pressreleaser Ladda ner | Visa Stäng
2019-06-10 Diamyd Medical Diamyd Medical AB: Diamyd Medical tecknar full ut sin andel i NextCell Pharmas företrädesemission Pressreleaser Ladda ner | Visa Stäng
2019-06-04 Diamyd Medical Diamyd Medical AB: Ny delrapport vid 30 månader och efter extra injektion stödjer långtidseffekt av intralymfatisk Diamyd® Pressreleaser Ladda ner | Visa Stäng
2019-06-04 Diamyd Medical Diamyd Medical AB: New interim report at 30 months and after extra injection supports long-term effect of intralymphatic Diamyd® Pressreleaser Ladda ner | Visa Stäng
2019-05-29 Diamyd Medical Diamyd Medical AB: The Swedish Medical Products Agency approves new treatment arm with Remygen® and Alprazolam in Phase I/II trial ReGenerate-1 Pressreleaser Ladda ner | Visa Stäng
2019-05-29 Diamyd Medical Diamyd Medical AB: Läkemedelsverket godkänner ny behandlingsarm med Remygen® och Alprazolam i fas I/II-studien ReGenerate-1 Pressreleaser Ladda ner | Visa Stäng
2019-05-13 Diamyd Medical Diamyd Medical AB: Huvudägare minskar innehav i Diamyd Medical med 0,6% Pressreleaser Ladda ner | Visa Stäng
2019-05-07 Diamyd Medical Diamyd Medical AB: Fully recruited European Phase IIb trial with the diabetes vaccine Diamyd® Pressreleaser Ladda ner | Visa Stäng
2019-05-07 Diamyd Medical Diamyd Medical AB: Fullrekryterad europeisk fas IIb-studie med diabetesvaccinet Diamyd® Pressreleaser Ladda ner | Visa Stäng
2019-04-16 Diamyd Medical Diamyd Medical AB: Resultat från EDCR IIa-studien där Diamyd® ges subkutant Pressreleaser Ladda ner | Visa Stäng
2019-04-16 Diamyd Medical Diamyd Medical AB: Results from the EDCR IIa trial where Diamyd® is given subcutaneously Pressreleaser Ladda ner | Visa Stäng
2019-04-11 Diamyd Medical Diamyd Medical AB: Immunological findings supporting intralymphatic treatment with Diamyd® to be presented today at a diabetes meeting in Stockholm Pressreleaser Ladda ner | Visa Stäng
2019-04-11 Diamyd Medical Diamyd Medical AB: Immunologiska resultat som stödjer intralymfatisk behandling med Diamyd® presenteras idag vid diabeteskonferens i Stockholm Pressreleaser Ladda ner | Visa Stäng
2019-03-28 Diamyd Medical Diamyd Medical AB: Penser Access: Diamyd Medical - DIAGNODE-2 nära fullrekryterad Pressreleaser Visa Stäng
2019-03-27 Diamyd Medical Diamyd Medical AB: Delårsrapport II 18/19 Rapporter Ladda ner | Visa Stäng
2019-03-27 Diamyd Medical Diamyd Medical AB: Quarterly Report II 18/19 Rapporter Ladda ner | Visa Stäng
2019-03-26 Diamyd Medical Diamyd Medical AB: Diamyd Medical informerar om strategiska aktiviteter 2019 och 2020 Pressreleaser Ladda ner | Visa Stäng
2019-03-26 Diamyd Medical Diamyd Medical AB: Diamyd Medical announces strategic activities for 2019 and 2020 Pressreleaser Ladda ner | Visa Stäng
2019-03-08 Diamyd Medical Diamyd Medical AB: Europeisk fas IIb-studie i typ 1-diabetes med diabetesvaccinet Diamyd® nära fullrekrytering Pressreleaser Ladda ner | Visa Stäng
2019-03-08 Diamyd Medical Diamyd Medical AB: European Phase IIb trial in type 1 diabetes with the diabetes vaccine Diamyd® close to being fully recruited Pressreleaser Ladda ner | Visa Stäng
2019-03-04 Diamyd Medical Diamyd Medical AB: A new publication supports Diamyd Medical's patent rights around GABA Pressreleaser Ladda ner | Visa Stäng
2019-03-04 Diamyd Medical Diamyd Medical AB: Ny publikation stödjer Diamyd Medicals patenträttigheter kring GABA Pressreleaser Ladda ner | Visa Stäng
2019-01-24 Diamyd Medical Penser Access: Diamyd - Finansiering säkrad Pressreleaser Visa Stäng
2019-01-23 Diamyd Medical Delårsrapport I 18/19 Rapporter Ladda ner | Visa Stäng
2019-01-23 Diamyd Medical Quarterly Report I 18/19 Rapporter Ladda ner | Visa Stäng
2018-12-20 Diamyd Medical 75 percent of patients now enrolled in Diamyd Medical's European Phase II trial Pressreleaser Ladda ner | Visa Stäng
2018-12-20 Diamyd Medical 75 procent av patienterna är nu rekryterade i Diamyd Medicals europeiska fas II-studie Pressreleaser Ladda ner | Visa Stäng
2018-12-06 Diamyd Medical Diamyd Medical tillförs 58,4 MSEK genom optionslösen Pressreleaser Ladda ner | Visa Stäng
2018-12-06 Diamyd Medical Diamyd Medical raises SEK 58.4 million in funds through redemption of warrants Pressreleaser Ladda ner | Visa Stäng
2018-11-28 Diamyd Medical Komplettering - Elva av tolv typ 1-diabetespatienter behandlade med intralymfatiskt Diamyd® i partiell remission vid 15 månader Pressreleaser Ladda ner | Visa Stäng
2018-11-26 Diamyd Medical Elva av tolv typ 1-diabetespatienter behandlade med intralymfatiskt Diamyd® i partiell remission vid 15 månader Pressreleaser Ladda ner | Visa Stäng
2018-11-26 Diamyd Medical Eleven out of twelve Type 1 diabetes patients treated with intralymphatic Diamyd® are in Partial Remission at 15 months Pressreleaser Ladda ner | Visa Stäng
2018-11-26 Diamyd Medical Diamyd Medical påminner om nyttjande av teckningsoptioner Pressreleaser Ladda ner | Visa Stäng
2018-11-15 Diamyd Medical Kommuniké från årsstämma i Diamyd Medical AB Pressreleaser Ladda ner | Visa Stäng
2018-11-15 Diamyd Medical Bulletin from Annual General Meeting of Diamyd Medical AB Pressreleaser Ladda ner | Visa Stäng
2018-11-15 Diamyd Medical Diamyd Medical updates on the Company and the diabetes vaccine Diamyd® ahead of the Annual General Meeting today Pressreleaser Ladda ner | Visa Stäng
2018-11-15 Diamyd Medical Diamyd Medical uppdaterar om Bolaget och diabetesvaccinet Diamyd® inför dagens årsstämma Pressreleaser Ladda ner | Visa Stäng
2018-11-14 Diamyd Medical Diamyd Medicals huvudägare ökar sin investering i Bolaget genom att fullt ut nyttja sina teckningsoptioner Pressreleaser Ladda ner | Visa Stäng
2018-11-01 Diamyd Medical Internationally renowned diabetes expert proposed to join Diamyd Medical's Board of Directors Pressreleaser Ladda ner | Visa Stäng
Pressreleaser | 1 Nov 2018 | Diamyd Medical

Internationally renowned diabetes expert proposed to join Diamyd Medical’s Board of Directors

”Having followed Diamyd Medical as a scientific advisor over many years, it is with great enthusiasm I will join the Company’s Board of Directors,” says Professor Mark Atkinson. ”I will do my best to continue to make a difference for those with type 1 diabetes”.

”Mark Atkinson is bringing invaluable expertise and experience to our Board,” says Anders Essen-Möller, founder and Board member of Diamyd Medical. ”As our therapeutic diabetes vaccine is entering into late stage development it is imperative we are the top of mind choice regarding future international strategic developments for finding a cure for the disease.”

Dr Atkinson’s research extends to understanding the immunological mechanisms underlying the formation of type 1 diabetes, with a primary goal to develop an effective method for preventing and reversing the disease.

”We are extremely proud and honored to welcome this world-leading expert in diabetes to take active part in Diamyd Medical,” says Ulf Hannelius, President and CEO of Diamyd Medical.

The Annual General Meeting of Diamyd Medical for the fiscal year 2017/2018 will be held on November 15, 2018, at 5 pm. at hotel Kung Carl, Birger Jarlsgatan 21 in Stockholm. Presentations are planned for by Professor Per-Ola Carlsson, Uppsala University Hospital and University of Uppsala, and Professor Johnny Ludvigsson, Linköping University. Professor Atkinson may participate for part of the meeting by video-call.

About Diamyd Medical 
Diamyd Medical is dedicated to finding a cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cell and medical technology.

Diamyd Medical develops the diabetes vaccine Diamyd®, for antigen-specific immunotherapy based on the exclusively licensed GAD-molecule. Diamyd® has demonstrated good safety in trials with more than 1,000 patients as well as effect in some pre-specified subgroups. Besides the Company’s own European Phase-II trial DIAGNODE-2, where the diabetes vaccine is administered directly into the lymph node, there are four investigator initiated clinical trials ongoing with Diamyd®. Diamyd Medical also develops Remygen®, an oral GABA-based investigational drug. An investigator-initiated trial in patients with type 1 diabetes since at least five years has started at Uppsala University Hospital. An investigator-initiated placebo-controlled trial with GABA and Diamyd® in patients recently diagnosed with type 1 diabetes is ongoing at the University of Alabama at Birmingham. Exclusive licenses for GABA and positive allosteric modulators of GABA receptors for the treatment of diabetes and inflammatory diseases constitutes alongside with the diabetes vaccine Diamyd® and Remygen® key assets. Diamyd Medical is also one of the major shareholders in the stem cell company NextCell Pharma AB and has holdings in the medtech company Companion Medical, Inc., San Diego, USA and in the gene therapy company Periphagen, Inc., Pittsburgh, USA.

Diamyd Medical’s B-share is traded on Nasdaq First North under the ticker DMYD B. FNCA Sweden AB is the Company’s Certified Adviser.

2018-11-01 Diamyd Medical Internationellt känd diabetesexpert föreslås till Diamyd Medicals styrelse Pressreleaser Ladda ner | Visa Stäng
2018-11-01 Diamyd Medical Nyttjandeperioden av teckningsoptioner i Diamyd Medical inleds idag Pressreleaser Ladda ner | Visa Stäng
2018-10-25 Diamyd Medical Årsredovisning 17/18 Rapporter Ladda ner | Visa Stäng
2018-10-23 Diamyd Medical New immunological results that support intralymphatic treatment with Diamyd® to be presented at the Immunology of Diabetes Society Congress Pressreleaser Ladda ner | Visa Stäng
2018-10-23 Diamyd Medical Nya immunologiska resultat som stödjer intralymfatisk behandling med Diamyd® presenteras på internationell diabeteskonferens Pressreleaser Ladda ner | Visa Stäng
2018-10-18 Diamyd Medical Kallelse till årsstämma i Diamyd Medical AB Pressreleaser Ladda ner | Visa Stäng
2018-10-16 Diamyd Medical The Phase I/II trial with Remygen® for the regeneration of insulin-producing cells is recruiting patients Pressreleaser Ladda ner | Visa Stäng
2018-10-16 Diamyd Medical Fas I/II-studien med Remygen® för återbildning av insulinproducerande celler rekryterar patienter Pressreleaser Ladda ner | Visa Stäng
2018-10-08 Diamyd Medical EP-Access: Diamyd Medical - På väg att lösa diabetesgåtan Pressreleaser Visa Stäng
2018-10-03 Diamyd Medical Year-End Report 17/18 Rapporter Ladda ner | Visa Stäng
2018-10-03 Diamyd Medical Bokslutskommuniké 17/18 Rapporter Ladda ner | Visa Stäng
2018-09-18 Diamyd Medical Diamyd Medical tydliggör målet att ansöka om tidigare marknadsgodkännande för Diamyd® Pressreleaser Ladda ner | Visa Stäng
2018-09-18 Diamyd Medical Diamyd Medical clarifies the goal of applying for earlier market approval for Diamyd® Pressreleaser Ladda ner | Visa Stäng
2018-09-11 Diamyd Medical Positive 15-month results with Diamyd® in Type 1 diabetes Pressreleaser Ladda ner | Visa Stäng
2018-09-11 Diamyd Medical Positiva 15-månadersresultat med Diamyd® i typ 1-diabetes Pressreleaser Ladda ner | Visa Stäng
2018-08-23 Diamyd Medical Diamyd Medical utnyttjar samtliga sina teckningsoptioner i NextCell Pharma Pressreleaser Ladda ner | Visa Stäng
2018-08-23 Diamyd Medical Diamyd Medical exercises all of its warrants in NextCell Pharma Pressreleaser Ladda ner | Visa Stäng
2018-08-21 Diamyd Medical Strategisk utökning av Diamyd Medicals europeiska fas II-studie i typ 1-diabetes Pressreleaser Ladda ner | Visa Stäng
2018-08-21 Diamyd Medical Strategic expansion of Diamyd Medical's European Phase II trial in Type 1 diabetes Pressreleaser Ladda ner | Visa Stäng
2018-08-21 Diamyd Medical Strategic expansion of Diamyd Medical's European Phase II trial in Type 1 diabetes Pressreleaser Ladda ner | Visa Stäng
2018-08-21 Diamyd Medical Strategisk utökning av Diamyd Medicals europeiska fas II-studie i typ 1-diabetes Pressreleaser Ladda ner | Visa Stäng
2018-07-04 Diamyd Medical The GABA/Diamyd® trial in the US now fully recruited Pressreleaser Ladda ner | Visa Stäng
2018-07-04 Diamyd Medical Den amerikanska GABA/Diamyd®-studien nu fullrekryterad Pressreleaser Ladda ner | Visa Stäng
2018-06-27 Diamyd Medical Delårsrapport III 17/18 Rapporter Ladda ner | Visa Stäng
2018-06-27 Diamyd Medical Quarterly Report III 17/18 Rapporter Ladda ner | Visa Stäng
2018-06-13 Diamyd Medical Diamyd Medicals Remygen™ för återbildning av insulinproducerande celler godkänt för kliniska studier Pressreleaser Ladda ner | Visa Stäng
2018-06-13 Diamyd Medical Diamyd Medical's Remygen™ for regeneration of insulin-producing cells approved for clinical trials Pressreleaser Ladda ner | Visa Stäng
2018-05-18 Diamyd Medical Update regarding the manufacturing of Diamyd® drug substance Pressreleaser Ladda ner | Visa Stäng
2018-05-18 Diamyd Medical Uppdatering gällande tillverkning av Diamyd® läkemedelssubstans Pressreleaser Ladda ner | Visa Stäng
2018-05-16 Diamyd Medical Läkemedelsverket godkänner en extra injektion Diamyd® i pågående pilotstudie Pressreleaser Ladda ner | Visa Stäng
2018-05-16 Diamyd Medical Swedish MPA approves an additional injection of Diamyd® in ongoing clinical pilot trial Pressreleaser Ladda ner | Visa Stäng
2018-05-07 Diamyd Medical Resultat som stödjer intralymfatisk behandling med Diamyd® publicerade i Journal of Diabetes Research Pressreleaser Ladda ner | Visa Stäng
2018-05-07 Diamyd Medical Results supporting intralymphatic administration of Diamyd® published in the Journal of Diabetes Research Pressreleaser Ladda ner | Visa Stäng
2018-04-23 Diamyd Medical 50% enrollment milestone reached in Diamyd Medical's European Phase II trial Pressreleaser Ladda ner | Visa Stäng
2018-04-23 Diamyd Medical 50% rekryteringsmilstolpe uppnådd i Diamyd Medicals europeiska fas II-studie Pressreleaser Ladda ner | Visa Stäng
2018-04-05 Diamyd Medical Resultat om GABAs betydelse i diabetes, patentsökta av Diamyd Medical och forskare vid Uppsala universitet, har publicerats i eBioMedicine Pressreleaser Ladda ner | Visa Stäng
2018-04-05 Diamyd Medical Results showing GABA's relevance for diabetes, patent filed by Diamyd Medical and Uppsala University scientist, published in eBioMedicine Pressreleaser Ladda ner | Visa Stäng
2018-03-28 Diamyd Medical Delårsrapport II 17/18 Rapporter Ladda ner | Visa Stäng
2018-03-28 Diamyd Medical Quarterly Report II 17/18 Rapporter Ladda ner | Visa Stäng
2018-03-27 Diamyd Medical Diamyd® subcutaneously continues to show weaker results than when administered intralymphatically Pressreleaser Ladda ner | Visa Stäng
2018-03-27 Diamyd Medical Diamyd® subkutant fortsätter visa svagare resultat än om det ges intralymfatiskt Pressreleaser Ladda ner | Visa Stäng
2018-03-12 Diamyd Medical Delrapport från DIAGNODE-1 visar fortsatt positivt kliniskt förlopp Pressreleaser Ladda ner | Visa Stäng
2018-03-12 Diamyd Medical Interim report from DIAGNODE-1 shows continued positive clinical course Pressreleaser Ladda ner | Visa Stäng
2018-03-02 Diamyd Medical Operational update on the diabetes vaccine Diamyd® and recombinant GAD Pressreleaser Ladda ner | Visa Stäng
2018-03-02 Diamyd Medical Operationell uppdatering om diabetesvaccinet Diamyd® och rekombinant GAD Pressreleaser Ladda ner | Visa Stäng
2018-02-22 Diamyd Medical GABA/Diamyd®-studien fullrekryterad till sommaren Pressreleaser Ladda ner | Visa Stäng
2018-02-22 Diamyd Medical The GABA/Diamyd®   trial in the US fully recruited this summer Pressreleaser Ladda ner | Visa Stäng
2018-02-09 Diamyd Medical Stort intresse från patienter att delta i DIAGNODE-2-studien Pressreleaser Ladda ner | Visa Stäng
2018-02-09 Diamyd Medical High interest from patients to participate in the DIAGNODE-2 trial Pressreleaser Ladda ner | Visa Stäng
2018-01-24 Diamyd Medical Delårsrapport I 17/18 Rapporter Ladda ner | Visa Stäng
2018-01-24 Diamyd Medical Quarterly Report I 17/18 Rapporter Ladda ner | Visa Stäng
2018-01-08 Diamyd Medical The diabetes vaccine Diamyd® shows continued positive clinical course after 30 months Pressreleaser Ladda ner | Visa Stäng
2018-01-08 Diamyd Medical Diabetesvaccinet Diamyd® visar fortsatt positivt kliniskt förlopp efter 30 månader Pressreleaser Ladda ner | Visa Stäng
2017-12-11 Diamyd Medical Diabetesvaccinet Diamyd® visar positiva resultat Pressreleaser Ladda ner | Visa Stäng
2017-12-11 Diamyd Medical The diabetes vaccine Diamyd® shows positive results Pressreleaser Ladda ner | Visa Stäng
2017-11-30 Diamyd Medical Bulletin from Annual General Meeting of Diamyd Medical AB Pressreleaser Ladda ner | Visa Stäng
2017-11-30 Diamyd Medical Kommuniké från årsstämma i Diamyd Medical AB Pressreleaser Ladda ner | Visa Stäng
2017-11-30 Diamyd Medical Preliminära 6-månadersresultat från DIAGNODE-1 innan jul Pressreleaser Ladda ner | Visa Stäng
2017-11-30 Diamyd Medical Preliminary 6-month results from DIAGNODE-1 before Christmas Pressreleaser Ladda ner | Visa Stäng
2017-11-21 Diamyd Medical The website www.diagnode-2.com launched for recruitment of patients for DIAGNODE-2 trial Pressreleaser Ladda ner | Visa Stäng
2017-11-21 Diamyd Medical Webbplatsen www.diagnode-2.com lanserad för patientrekrytering till studien DIAGNODE-2 Pressreleaser Ladda ner | Visa Stäng
2017-11-14 Diamyd Medical Diamyd Medicals vd har köpt aktier i Bolaget Pressreleaser Ladda ner | Visa Stäng
2017-11-14 Diamyd Medical Diamyd Medical's CEO purchased shares in the Company Pressreleaser Ladda ner | Visa Stäng
2017-11-13 Diamyd Medical Fas II-studien DIAGNODE-2 är nu inför Världsdiabetesdagen öppen att ta in patienter Pressreleaser Ladda ner | Visa Stäng
2017-11-13 Diamyd Medical Phase II-trial DIAGNODE-2 ahead of World Diabetes Day now open to include patients Pressreleaser Ladda ner | Visa Stäng
2017-11-09 Diamyd Medical Årsredovisning 16/17 Rapporter Ladda ner | Visa Stäng
2017-11-02 Diamyd Medical Kallelse till årsstämma i Diamyd Medical AB Pressreleaser Ladda ner | Visa Stäng
2017-10-27 Diamyd Medical Update concerning prevention studies with the diabetes vaccine Diamyd® Pressreleaser Ladda ner | Visa Stäng
2017-10-27 Diamyd Medical Uppdatering avseende preventionsstudier med diabetesvaccinet Diamyd® Pressreleaser Ladda ner | Visa Stäng
2017-10-24 Diamyd Medical Diamyd Medical strengthens GABA portfolio with new license Pressreleaser Ladda ner | Visa Stäng
2017-10-24 Diamyd Medical Diamyd Medical stärker GABA-portföljen med ny licens Pressreleaser Ladda ner | Visa Stäng
2017-10-11 Diamyd Medical Financial Statement 16/17 Rapporter Ladda ner | Visa Stäng
2017-10-11 Diamyd Medical Bokslutskommuniké 16/17 Rapporter Ladda ner | Visa Stäng

Kommande händelser

10 Oct 2018 | Bokslutskommuniké 2018
15 Nov 2018 | Årsstämma 2018
16 Nov 2018 | Årligutdelning
23 Jan 2019 | Kvartalsrapport 2019-Q1
27 Mar 2019 | Kvartalsrapport 2019-Q2
26 Jun 2019 | Kvartalsrapport 2019-Q3
2 Oct 2019 | Bokslutskommuniké 2019

epaccess.penser.se använder cookies för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder cookies. Vad är cookies?

Jag godkänner